Exelixis, Inc. (NASDAQ:EXEL) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. reduced its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 27.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,506,084 shares of the biotechnology company's stock after selling 576,199 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.53% of Exelixis worth $50,153,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Coppell Advisory Solutions LLC acquired a new position in Exelixis in the 4th quarter valued at $25,000. Colonial Trust Co SC grew its holdings in Exelixis by 616.9% in the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after buying an additional 765 shares in the last quarter. USA Financial Formulas purchased a new stake in Exelixis in the 4th quarter valued at $32,000. Principal Securities Inc. grew its holdings in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after buying an additional 373 shares in the last quarter. Finally, Kestra Investment Management LLC purchased a new stake in Exelixis in the 4th quarter valued at $39,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Trading Up 3.6%

EXEL traded up $1.61 during mid-day trading on Thursday, hitting $46.26. 10,313,747 shares of the stock were exchanged, compared to its average volume of 2,254,251. The firm's fifty day moving average is $36.92 and its two-hundred day moving average is $35.56. Exelixis, Inc. has a 1-year low of $20.14 and a 1-year high of $48.83. The company has a market cap of $12.75 billion, a PE ratio of 26.14, a PEG ratio of 1.13 and a beta of 0.25.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. As a group, research analysts anticipate that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Buying and Selling

In other Exelixis news, EVP Dana Aftab sold 1,508 shares of the stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $39.00, for a total value of $58,812.00. Following the sale, the executive vice president now owns 693,181 shares of the company's stock, valued at $27,034,059. This trade represents a 0.22% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Mary C. Beckerle sold 12,210 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares in the company, valued at $1,060,561.28. This represents a 28.65% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 141,851 shares of company stock valued at $5,236,046. Corporate insiders own 2.82% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on EXEL shares. UBS Group restated an "underperform" rating on shares of Exelixis in a report on Thursday, April 17th. Truist Financial upped their target price on Exelixis from $42.00 to $43.00 and gave the company a "buy" rating in a report on Monday, January 27th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a report on Thursday, April 17th. Guggenheim reiterated a "buy" rating and set a $42.00 price target on shares of Exelixis in a report on Wednesday, February 12th. Finally, Barclays increased their price target on Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $38.76.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.